Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.

類似資料

• Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.
  著者:: Reed, E, 等
  出版事項: (1986)
• Polyclonal antibodies to quantitate cis-diamminedichloroplatinum(II)--DNA adducts in cancer patients and animal models.
  著者:: Poirier, M C, 等
  出版事項: (1985)
• Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.
  著者:: Dabholkar, M, 等
  出版事項: (1994)
• Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.
  著者:: Dimitra T Stefanou, 等
  出版事項: (2015-01-01)
• Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer
  著者:: Stefanou, Dimitra T., 等
  出版事項: (2015)